Sam Cooper, CEO of Phenomic AI, on Automated HCS and More - podcast episode cover

Sam Cooper, CEO of Phenomic AI, on Automated HCS and More

Jun 28, 201824 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

On this episode, I speak with Sam Cooper, cofounder and CEO of Phenomic AI ( www.phenomic.ai ). Sam and his team use machine learning for automated image analysis to study cell biology and screen drugs. But that’s just the beginning. In this episode, you’ll learn about Phenomic’s distinct approach to drug discovery, its use of machine learning for high content screening, and how they plan to scale from a technology company to a full stack biotech business. This episode is brought to you by BenchSci ( www.benchsci.com ). BenchSci uses artificial intelligence to reduce the cost of scientific experiments. Use it to find research antibodies up to 24x faster than using PubMed or Google Scholar. Just enter a protein of interest and filter by technique, organism, tissue, or several other options. BenchSci returns only relevant published figures and products. It’s free for academic researchers. Learn more and sign up at www.benchsci.com .
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast
Sam Cooper, CEO of Phenomic AI, on Automated HCS and More | Artificial Intelligence in Drug Discovery podcast - Listen or read transcript on Metacast